HilleVax, Inc.

HLVX

US43157M1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
12.79 ^USD	+6.41%		+3.98%	-20.31%

Apr. 05	Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing	MT
Mar. 21	Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating	MT

HilleVax Taps Sean McLoughlin as Chief Operating Officer

January 18, 2024 at 07:35 am EST

By Ben Glickman

HilleVax on Thursday named Sean McLoughlin as the vaccine developer's next operating chief.

The Boston-based biopharmaceutical company said that co-founder and current COO Aditya Kohli will become chief business officer as part of a planned transition.

McLoughlin, 52, recently served as global vaccine commercialization lead, RSV at GSK. He has held various roles at GSK over 25 years with the company.

McLoughlin will receive an annual base salary of $450,000, with an annual target bonus of 45% of his salary and a sign-on bonus of $200,000.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

01-18-24 0734ET

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	GSK PLC	1,653 GBX	+0.76%	+3.38%	84.13B
	HILLEVAX, INC.	12.79 USD	+6.41%	+3.98%	616M

Latest news about HilleVax, Inc.

Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing	Apr. 05	MT
Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating	Mar. 21	MT
HilleVax Insider Sold Shares Worth $985,536,428, According to a Recent SEC Filing	Mar. 21	MT
HilleVax Proposes $500 Million Offering of Equity, Debt Securities in Shelf Registration	Mar. 20	MT
HilleVax Q4 Net Loss Widens; Shares Extend Decline After Hours	Mar. 20	MT
HilleVax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
HilleVax, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 20	CI
HilleVax Names New Chief Operating Officer	Jan. 18	MT
HilleVax Taps Sean McLoughlin as Chief Operating Officer	Jan. 18	DJ
HilleVax, Inc. Announces Executive Changes	Jan. 18	CI
Kanghua Biological Products Licenses Norovirus Vaccine to HilleVax	Jan. 08	MT
Certain Options of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023.	Dec. 18	CI
Certain Restricted Stock Units of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023.	Dec. 18	CI
Certain Common Stock of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023.	Dec. 18	CI
HilleVax, Inc.(NasdaqGS:HLVX) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
HC Wainwright Initiates HilleVax With Buy Rating	Dec. 13	MT
Hillevax Insider Sold Shares Worth $287,000, According to a Recent SEC Filing	Dec. 05	MT
Hillevax Insider Sold Shares Worth $140,000, According to a Recent SEC Filing	Nov. 20	MT
HilleVax Q3 Net Loss Widens	Nov. 09	MT
HilleVax, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
HilleVax Prices $100 Million Common Stock Offering	23-09-20	MT
HilleVax, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
HilleVax, Inc. Enters into a First Amendment to Loan and Security Agreement with Hercules Capital, Inc	23-06-22	CI
JPMorgan Adjusts Price Target on HilleVax to $22 From $23, Maintains Overweight Rating	23-05-16	MT
HilleVax Files Up to $500 Million Mixed-Securities Shelf	23-05-15	MT

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.79 USD

Average target price

29 USD

Spread / Average Target

+126.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HILLEVAX, INC.	-20.31%	616M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

HilleVax, Inc.

Equities

HLVX

US43157M1027

Biotechnology & Medical Research

HilleVax Taps Sean McLoughlin as Chief Operating Officer

Stocks mentioned in the article

Latest news about HilleVax, Inc.

Chart HilleVax, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research